During COMy 2020, Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about genomics of high-risk MM.
Here, Nikhil Munshi highlights the positive shift in survival outcomes of patients with high-risk MM in recent years, owing to emerging treatments and diagnostic techniques. Three major points are discussed:
1. Who is high risk?
2. What are the characteristics of high-risk MM?
3. How do we treat patients with high-risk disease?
Hosted on Acast. See acast.com/privacy for more information.
